Arbutus Biopharma Corporation ABUS Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Revenue by Product | |||||
| Collaborations and licenses | $12.6M+222% | $3.92M-72.5% | $14.27M-54.5% | $31.37M+543% | |
| Non-cash royalty revenue | $1.48M-34.2% | $2.25M-41.8% | $3.87M-49.5% | $7.65M+25.3% | |
| Revenue from collaborations and licenses | $10.71M+318% | $2.56M-76.1% | $10.7M-58.9% | $26.06M+458% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Arbutus Biopharma Corporation break its business down?
- Arbutus Biopharma Corporation (ABUS) reports revenue by product across 3 parts — Collaborations and licenses, Non-cash royalty revenue and Revenue from collaborations and licenses. Each is extracted from the segment footnotes and tracked over time.
- Where does Arbutus Biopharma Corporation's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Arbutus Biopharma Corporation's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
